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Abstract
Lysine deacetylases (KDACs) are enzymes that reverse the post-translational modification of 
lysine acetylation. Thousands of potential substrates, acetylated protein sequences, have been 
identified in mammalian cells. Properly regulated acetylation and deacetylation have been linked 
to many biological processes, while aberrant KDAC activity has also been linked to numerous 
diseases. Commercially available peptide substrates that are conjugated to fluorescent dye 
molecules, such as 7-amino-4-methylcoumarin (AMC), are commonly used to monitor 
deacetylation in studies addressing both substrate specificity and small molecule modulators of 
activity. Here, we have compared the activity of several KDACs, representing all major classes of 
KDACs, with substrates in the presence and absence of AMC as well as peptides for which 
tryptophan has been substituted for AMC. Our results unequivocally demonstrate that AMC has a 
significant effect on activity for all KDACs tested. Furthermore, the effect is not consistent across 
KDACs, neither in nature of the effect nor magnitude, making it impossible to predict the effect of 
AMC on a particular enzyme-substrate pair. AMC did not affect acetyllysine preference in a 
multiply acetylated substrate. In contrast, AMC significantly enhanced KDAC6 substrate affinity, 
greatly reduced Sirt1 activity, eliminated substrate sequence specificity of KDAC4, and had no 
consistent effect with KDAC8 substrates. These results indicate that profiling of KDAC activity 
with labeled peptides is unlikely to produce biologically relevant data.
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Introduction
Lysine deacetylases (KDACs) are enzymes that reverse the post-translational modification of 
lysine acetylation, by catalyzing the hydrolysis of ε-N-acetyllysine residues in proteins. The 
eighteen human KDACs are divided into several classes. Classes I, IIa, and IIb are metal-
dependent enzymes that share a conserved reaction mechanism, and are often referred to as 
histone deacetylases. 1-3 Class III KDACs, or sirtuins, are NAD+-dependent enzymes that 
catalyze the same net reaction but are unrelated to the metal-dependent KDACs. The metal-
dependent KDAC11 is sometimes considered to be its own class, class IV.4,5 Thousands of 
acetylated protein sequences have been identified in mammalian cells, and thus are 
potentially subject to deacetylation by KDACs.6-11 However, direct evidence for 
deactylation of acetylated proteins by a specific KDAC exists for only a small number of 
potential non-histone KDAC substrates.12-15 Properly regulated acetylation and 
deacetylation have been linked to many biological processes, while aberrant KDAC activity 
has also been linked to numerous diseases.4,5 Based on the therapeutic potential of 
regulating KDACs in vivo, research efforts are focused on identifying molecules that inhibit 
or activate these enzymes,5,16-18 as well as identifying substrates of specific KDACs.19-23
To address these research questions, several in vitro assays have been developed to measure 
KDAC activity with a variety of substrates. One common method utilizes peptide substrates, 
which are often derived from acetylated human proteins, that are conjugated to fluorescent 
dye molecules, such as 7-amino-4-methylcoumarin (AMC). In these assays, fluorescence of 
AMC occurs only when the dye molecule is cleaved from the peptide by trypsin, which is 
dependent on deacetylation.20 As several of these substrates are commercially available, 
they are heavily utilized for determining the effects of small molecules on enzyme activity 
and characterizing substrate interactions.24,25 In addition, this method has been used to 
investigate substrate preferences for specific KDACs, although it can only be used to 
investigate the residues on the N-terminal side of the acetylated lysine. In one instance, to 
address substrate specificity of KDACs, activity was determined for several KDACs against 
peptides containing different combinations of amino acids at the -2 and -1 positions relative 
to the acetylated lysine and with AMC conjugated to the C-terminal side.22 While 
convenient, these assays assume that the presence of AMC does not affect the enzyme’s 
function or substrate preferences. Such effects, especially any that is not consistent for 
multiple enzymes and substrates, would greatly impact how the results of such experiments 
can be interpreted, even when the peptide to which the AMC is conjugated is derived from a 
known substrate protein sequence.
Recently, we developed an assay which enables monitoring the activity of KDACs without 
use of a conjugated dye or other unnatural modification of substrate.26 This method relies on 
fluorescamine, a molecule that reacts with primary amines, resulting in fluorescence.27 
Fluorescamine is particularly suited for this application, as it specifically reacts with the 
product of deacetylation (i.e. an unacetylated lysine) and therefore monitors deacetylation of 
unlabeled substrates. Notably, we found that normalizing the activity from a library of AMC 
conjugated peptides did not correlate with the activity obtained with unlabeled 5-mer 
peptides with the same amino acids at the -2 and -1 positions relative to the acetylated 
lysine.26 In contrast, our results did correlate with an alternate assay for label-free substrates 
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based on detection of acetate.28 Therefore, the AMC conjugated peptides did not serve as 
reliable predictors for substrates of KDAC8. While this discrepancy could be due, at least in 
part, to the contribution of the amino acids in the +1 and +2 positions relative to the 
acetylated lysine, it may also be that the presence of AMC adjacent to the acetylated lysine 
affects the activity of the enzyme in a manner that is not biologically relevant. Notably, other 
groups have reported isolated instances where AMC conjugation to specific peptides led to 
increased activity with KDACs on specific substrates when compared to the use of other 
methods for detection of deacetylation.23,28,29 In addition, small molecule activators of some 
KDACs have been reported to be sequence-specific, and activators identified using AMC-
conjugated substrates have not demonstrated activation with unlabeled substrates.30-33 
However, to date no work has been reported that systematically probes the underlying 
mechanism of activity changes caused by AMC conjugation across multiple substrates and 
classes of KDACs.
To directly determine whether AMC affects KDAC activity when conjugated to peptide 
substrates in a more comprehensive way, we assayed the activity of several KDACs with 
three different commercially available AMC-conjugated substrates and compared the 
activity to the activity with the corresponding non-AMC conjugated peptides. The results 
demonstrated a clear, significant effect of the dye on activity for all classes of KDACs. 
Furthermore, the effect was not consistent for the different enzymes, making interpretation 
of previously collected data more challenging.
Methods
KDAC expression and purification
pFastbac1 (Life Technologies) containing human KDAC8 (Uniprot Q9BY41), fused to a 
tobacco-etch virus (TEV) protease cleavage site and His6 tag, was transformed into 
DH10Bac E. coli cells to produce bacmids containing KDAC8.34 Bacmids were purified and 
transfected into Sf9 cells using Cellfectin II (Life Technologies) as described elsewhere.35 
Baculovirus from these transfections was then used to infect High Five insect cells in 
suspension. At 72 hours post-infection, cells were pelleted and frozen at -20 °C until lysis. 
Cells were resuspended in lysis buffer (30 mM MOPS pH 8.0, 150 mM KCl, 5% glycerol, 5 
mM imidazole, 2 mM MgCl2, 1X HALT protease inhibitor [Thermo Scientific]). 
Purification was then performed as described previously.26 KDAC6 (Uniprot Q9UBN7, a 
gift from Eric Verdin, Addgene plasmid #13823)36 was cloned into pFastBac1 with the TEV 
protease cleavage site and His6 tag, then expressed and purified in insect cells using the 
same protocol as for KDAC8 except that the His6 tag was retained. Sirt1(193-741)-GST 
(Uniprot Q96EB6) was obtained from BPS Bioscience and dialyzed into KDAC storage 
buffer (30 mM MOPS pH 8.0, 150 mM KCl, 25% glycerol, 1 mM tris(2-
carboxyethyl)phosphine). KDAC4(648-1057) (Uniprot P56524) was synthesized as a codon-
optimized gene in pJExpress401 (DNA 2.0), then expressed and purified as previously 
described for KDAC8.26 Site-directed mutagenesis was used to create KDAC4 H976Y 
(KDAC4HY), which was then expressed and purified identically.
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KDAC substrates
All peptides were N-terminally acetylated, and unlabeled peptides C-terminally amidated. 
{K-ac} was synthesized by adding ten-fold molar excess anhydrous acetic anhydride to 
acetyl-L-lysine amide hydrochloride (Chem-Impex International) in anhydrous DMSO. The 
sealed reaction was allowed to proceed for 3 days at room temperature. After confirmation 
of complete acetylation using fluorescamine, 2.5% dH2O was added to the reaction and it 
was dried using a vacuum concentrator until all solvent evaporated. Purity and complete 
acetylation were confirmed by NMR (Table S1). Fluorophore-coupled substrates were 
obtained commercially (Enzo Life Sciences, R&D Systems, or BPS Bioscience). All other 
substrates were commercial custom peptide syntheses purified to > 95% (Genscript).
Activity assays
Assays were performed as described previously.26 For endpoint assays, 100 μM substrate 
was incubated with KDAC8 (200 nM), Sirt1 (200 nM), KDAC6 (50 nM), KDAC4 (200 nM), 
or KDAC4HY (200 nM for unlabeled peptides, 10 nM for labeled substrates) for 1 hour at 
25 °C. For kinetic analyses, at least eight concentrations of each peptide substrate were 
incubated with 10-50 nM KDAC6 or 150 nM KDAC8 in reaction buffer at 25 °C. Aliquots 
were taken at five timepoints and added to SAHA (suberoylanilide hydroxamic acid) at a 
final concentration of 100 μM. Timepoints for each substrate were selected to ensure that the 
data reflected the initial velocity of the reaction and varied between 1 and 60 minutes in 
increments of 0.25 to 15 minutes. Michealis-Menten steady state parameters were calculated 
as described previously,26 using at least three consecutive and linear data points for each 
concentration, again to ensure that calculations reflected initial velocity.
KDAC reactions assayed by MALDI MS
Several concentrations of KDAC6 and KDAC8 were incubated with 50 μM substrate for 
either 10 min (KDAC6) or 60 min (KDAC8) at 25 °C. Reactions were stopped by adding 
SAHA to a final concentration of 100 μM. The reaction was diluted 1:100 in TA85 (85% 
acetonitrile, 15% water, 0.1% trifluoroacetic acid). 0.5 μl was spotted onto a MTP 
Anchorchip target plate (Bruker Daltonics) and allowed to dry. 0.5 μl matrix (1.4 mg/ml α-
cyano-4-hydroxycinnamic acid in TA85) was spotted on top of each sample. Samples were 
analyzed by matrix assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass 
spectrometry (MS) on an Autoflex Speed MALDI TOF/TOF (Bruker Daltonics) in positive 
reflector mode and masses were assigned to peaks using flexanalysis software (Bruker 
Daltonics). For each enzyme-substrate pair containing the highest enzyme concentration, 
samples were also analyzed in LIFT mode to obtain MS/MS spectra for the substrate and 
products. Spectra were analyzed in flexanalysis for the presence or absence of diagnostic y-
ion peaks to distinguish between deacetylation at lysine positions 3 and 4, and the presence 
of expected a-ion, b-ion, and y-ion peaks confirmed by sequencing analysis using Biotools 
(Bruker Daltonics).
Results
To investigate whether the presence of AMC in substrates affected KDAC activity, we 
performed quantitative assays with metal-dependent KDACs (KDAC4, KDAC6, and 
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KDAC8) as well as a NAD+-dependent KDAC (Sirt1) as representative members of each 
major class of KDAC (class IIa, IIb, I, and III, respectively). Each KDAC was allowed to 
react with three sets of peptide substrates. Each substrate set included a base sequence where 
the acetylated lysine was at the C-terminus, a peptide that was identical except AMC was 
conjugated to the C-terminal side of the acetylated lysine, and a third peptide where a 
tryptophan (W) residue was included instead of the dye molecule at the +1 position (Figure 
1). We hypothesized that the tryptophan side chain would at least partially mimic the effect 
of AMC, as both are large, hydrophobic molecules. The three AMC-containing peptides 
were obtained from commercial sources and activity was assessed by measuring the 
fluorescence of free AMC after treatment with trypsin to liberate AMC from deacetylated 
peptides. Activity against the remaining peptides was quantified using the fluorescamine 
assay. Unfortunately, we found that free AMC interferes with the fluorescamine signal such 
that we could not assess deacetylation of AMC-containing peptides using the fluorescamine 
assay; however, the resulting activity measurements can be directly compared, as specific 
activity was calculated in each case. We have previously determined that specific activity 
from the fluorescamine assay is comparable to measurements obtained using other methods.
26
Strikingly, the presence of AMC in the peptide greatly affected the activity of all KDACs 
tested, resulting in a significant difference between deacetylation of the peptides with and 
without AMC in every case where activity was observed (Figure 2 and Table S2). As 
expected, KDAC4 did not demonstrate activity with any of the peptides tested; however, it 
was active with a previously reported class IIa fluorogenic substrate that is not biologically 
relevant,37 indicating that it was a functional enzyme (data not shown). Thus, we used a 
previously reported KDAC4 gain-of-function variant (KDAC4HY),37 which allowed us to 
determine the effect of the fluorophore on a class IIa KDAC. The overall effects of the dye 
were not consistent across KDACs. The dye increased activity for the metal-dependent 
KDACs, but not equivalently. In particular, KDAC4HY activity increased up to 300-fold 
with the AMC-containing peptides, compared to approximately 10-fold for KDAC6 and a 
widely variable amount for KDAC8. In addition, KDAC4HY was equivalently active with 
all three AMC-containing peptides, although there were clear differences in activity with the 
non-AMC containing peptides. In contrast, Sirt1 demonstrated negligible activity when 
AMC was present despite having significant activity with the unlabeled substrates. In all 
cases except KDAC4HY, the presence of tryptophan substantially increased activity over the 
base peptides. For KDAC6 and KDAC8, this resulted in an intermediate level of activity, 
suggesting that the tryptophan may be partially compensating for the AMC dye. However, 
this pattern was not apparent for Sirt1 or KDAC4HY, where inclusion of the tryptophan 
resulted in no significant change in activity compared to the base peptide (KDAC4HY) or 
the highest level of activity (Sirt1). Taken together, there was no discernible pattern for the 
effect of either tryptophan or AMC on KDAC activity across enzyme classes.
To determine whether the apparently similar effect of AMC on the activity of KDAC6 and 
KDAC8 shared an underlying mechanism, we determined the steady-state kinetic parameters 
for both KDAC6 and KDAC8 to determine whether the dye affected catalytic activity, 
substrate affinity, or both. We hypothesized that tryptophan and AMC both elicited their 
effects by influencing the affinity of the enzyme for each substrate. Reactions were set up 
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such that several concentrations of substrate were incubated with each KDAC and aliquots 
were taken at several different timepoints. We noticed that while KDAC6 deacetylated all 
substrates tested, for most substrates the reaction only proceeded at the initial velocity for a 
short time before slowing down and in many cases halting entirely, even though there was 
still a large excess of substrate present in the reaction (data not shown). The decrease in 
velocity was substrate-dependent rather than time-dependent, observed with some substrates 
in under 3 minutes; in contrast, KDAC6 maintained a constant velocity for at least one hour 
with other substrates. Therefore, we adjusted the timescale of each experiment to include 
only timepoints that reflected the true initial velocity. Steady-state kinetic parameters (kcat 
and KM) for each peptide with KDAC6 are shown in Table 1. While there were only modest 
differences in the rate of catalysis (kcat) between the peptides (only a 3.5 fold difference 
between the best and worst substrates), the substrate affinity varied dramatically. As with the 
endpoint data, a clear pattern emerged where the KM for each AMC-containing peptide was 
approximately 50-fold lower than the corresponding peptide without AMC. As expected, 
activity differences could not be attributed to differential effects of the inhibitor in the 
presence of AMC, as SAHA inhibition of KDAC6 was comparable in the presence and 
absence of AMC (Figure S1). Also consistent with the endpoint data, KDAC6 demonstrated 
intermediate affinity for the tryptophan-containing peptides in each case. The kinetic 
parameters for KDAC8 could not be definitively determined in all cases due to the relatively 
low activity of KDAC8 with some of the tested substrates (Table 1). However, it is apparent 
that KDAC8 does not follow a consistent trend in the same way that KDAC6 does, as the 
AMC-containing peptides increase or decrease kcat up to 10-fold depending on peptide 
sequence. Affinity does tend to increase (lower KM) with AMC-containing peptides, but to a 
much smaller degree than with KDAC6. Moreover, the tryptophan-containing peptides do 
not follow neatly in affinity between the other two substrates in each set. Similarly, the 
catalytic efficiency of KDAC6 is at least 4-fold greater for tryptophan-containing peptides 
and at least 25-fold greater for AMC-containing peptides compared to substrates with 
neither, while KDAC8 catalytic efficiency tends to increase in the same general trend but 
with greatly reduced magnitude of effect.
We recognized that the interpretation of the data generated for the RH{K-ac}{K-ac} peptide 
series may not be straightforward because it contains two acetylated lysines, and we are 
unaware of any report describing the ability of KDACs to deacetylate one position versus the 
other for this sequence. To determine whether one or both acetyllysines were substrates for 
KDAC6 and/or KDAC8, we used MALDI mass spectrometry to determine how many 
deacetylation events were occurring on both the RH{K-ac}{K-ac}W and RH{K-ac}{K-ac}-
AMC peptides. In all cases, only a singly deacetylated product appeared under conditions of 
lower KDAC concentration. When more enzyme was added, a doubly deacetylated product 
was observed in addition to the singly deacetylated product (Figure 3). Because the singly 
deacetylated product peak could be due to deacetylation at position 3, position 4, or a 
combination of two products, we further analyzed the peaks by tandem mass spectrometry. 
The lysine at position 4 was always deacetylated first, as the singly deacetylated products 
were identified as RH{K-ac}KW and RH{K-ac}K-AMC, indicating that both KDAC6 and 
KDAC8 demonstrate a preference for the second acetyllysine (Figure 4). Based on these 
observations, we can conclude that the Michaelis-Menten kinetic parameters calculated are 
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valid, as the reaction conditions used in the kinetic experiments were far below the threshold 
conditions necessary to observe the second deacetylation event and the qualitative trend of 
the MS data confirms that percent product formation was very low during the time scale 
used for our initial velocity.
Discussion
Prior to this report, limited data suggested that conjugated fluorophores may affect KDAC6 
and KDAC8 activity against model substrates.23,28,29 In one instance, AMC-based activity 
enhancement was previously observed for KDAC8 with the RH{K-ac}{K-ac} peptide using 
a mass spectrometry method.23 Our experiments demonstrate that this result is not substrate-
specific, as all three sets of peptides tested here display very clear effects of AMC 
incorporation. For the metal-dependent KDACs tested, the presence of AMC led to a large 
increase in activity (Figure 2 and Table S2). These results are consistent with previously 
reported data for KDAC8 with another set of peptides assayed using a distinct method,28 and 
the values of kcat and KM we determined are consistent with available prior data for some of 
the AMC-containing peptides,3,38-40 with variation in kcat related to known effects of 
different reaction conditions that we have previously reported on.26,41 KDAC6 was 
previously shown to exhibit greater endpoint activity with a peptide containing C-terminal 
acetyllysine compared to a corresponding peptide with AMC in the C-terminal position.29 
This result is not directly comparable to ours as we did not investigate any peptides with 
acetyllysine in the extreme C-terminal position and a free C-terminal carboxylate; however, 
it does reinforce that inclusion of AMC affects KDAC behavior.
Of particular interest is the fact that although KDAC6 and KDAC8 exhibited similar overall 
rate enhancement due to the AMC in endpoint assays, the underlying mechanism is entirely 
due to enhanced substrate affinity (i.e. lower KM values) in KDAC6, whereas KDAC8 
demonstrated variation in both substrate affinity and catalytic ability (Table 1). We are 
unaware of any direct comparison of peptides with and without the AMC fluorophore for 
KDAC6, but prior data characterizing steady-state kinetics of KDAC6 resulted in KM values 
similar to those we observed, with AMC-containing peptides consistently much lower than 
unlabeled peptides and with relatively little variation in kcat.29,42-44 We did note a significant 
difference in magnitude between some previously reported kcat values for KDAC6 and those 
generated here, where our values were 3- to 5-fold higher, especially for the AMC-
containing substrates.29,44 These differences can be attributed to the abrupt deceleration of 
KDAC6 that we observed, which occurs long before the substrate is significantly depleted. If 
the activity is calculated from a reaction which was allowed to proceed past this point, the 
kcat will be significantly underestimated. This also explains why our steady-state parameters 
predict endpoint velocities approximately 2-fold higher than actually observed for KDAC6, 
whereas the steady-state parameters reliably predict endpoint activity values for KDAC8. 
This behavior of KDAC6 must be considered when evaluating endpoint data, such as in 
inhibitor screens, because the assumption of constant velocity throughout the reaction over 
an extended period is invalid for this enzyme under typical in vitro reaction conditions. The 
underlying mechanism of this behavior of KDAC6 is an area of future investigation, 
potentially related to the fact that class IIb KDACs contain two catalytic domains.
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The largest AMC-dependent activity enhancement was observed for KDAC4HY, which 
increased activity 100-fold in some cases compared to the non-AMC containing peptide 
(Figure 2C and Table S2). Notably, while KDAC4HY showed distinct preferences among 
the non-AMC containing peptides, this specificity was lost upon the addition of AMC, as the 
activity with all three of the AMC-containing peptides was very similar. The trend was 
opposite for Sirt1, which is not metal dependent, as Sirt1 demonstrated negligible reactivity 
with AMC-containing peptide derivatives, but showed clear activity with each non-AMC 
containing counterpart (Figure 2D and Table S2). A previous report with a related peptide 
also demonstrated reduced activity of Sirt1 when AMC is conjugated.32 Overall, it is clear 
that AMC does not affect all KDACs in the same manner, and the activity of each KDAC is 
uniquely impacted.
While limited observations have previously suggested that conjugated dyes might enhance 
KDAC activity with peptide substrates, AMC and other dye conjugated substrates continue 
to be widely used to study KDACs, including substrate specificity and small molecule 
inhibitors and activators. This report directly demonstrates that AMC affects activity of 
KDACs of all classes in a manner independent of the substrate sequence. Together, the 
results presented here call into question the conclusions drawn from experiments using 
AMC-modified substrates. Certainly, KDAC activity with an AMC-conjugated substrate 
does not necessarily correlate to activity with a corresponding natural substrate, even for 
AMC-conjugated peptides derived from known substrates such as those utilized here, as the 
KDACs interact very differently with peptides in the presence of the dye. We have 
previously demonstrated that libraries of AMC-containing peptides did not reliably predict 
activity of KDAC8 with unlabeled substrates,26 and the results presented here indicate that 
the lack of correlation between labeled and unlabeled substrates applies to all KDACs. 
Therefore, profiling of KDAC activity with labeled peptides is unlikely to produce 
biologically relevant data.
In addition, a prior study suggested that the dye may have a differential effect on KDACs 
depending upon whether they are in a complex with other proteins. Specifically, KDAC3-
SMRT activity against the RH{K-ac}{K-ac} peptide was not affected by the presence or 
absence of the AMC dye; however, KDAC3 alone demonstrated activity with another AMC-
containing peptide but did not show activity with any non-dye containing peptides in a 
screen.23 This result is significant because in vivo KDAC3 exists in a complex containing 
SMRT, which has been reported to be essential for KDAC3’s activity,45,46 suggesting that 
the dye enhances activity in a manner that is not biologically relevant. All of these 
observations indicate that the effects of the dye are not consistent, neither in magnitude nor 
direction of effect, so it would not be possible to predict the effect of the dye for a particular 
substrate-KDAC pair.
While this report focused on the commercially-available AMC-containing substrates, several 
other fluorogenic substrates have been recently developed including those for removal of 
other acyl modifications by sirtuins.47-49 For example, “green” substrates based on 
fluorescien are now available and should also be used with caution, as these substrates 
utilize a larger fluorophore and are often dual substrates conjugated to a single fluorophore, 
and therefore deviate more than AMC-containing substrates from a biological context. Other 
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recently developed substrates allow deacetylation to be monitored in a single-step.24,50,51 
For some of these substrates, the dyes are positioned further away from the acetylated lysine 
than for the AMC substrates;52,53 however, it will be important to determine how the 
configuration of these substrates affects KDAC activity. An assumption that AMC or other 
fluorophores might mimic large non-polar residues after the acetyllysine is clearly incorrect, 
as tryptophan in the +1 position causes distinctly different activity effects than AMC. 
Although fluorophore-conjugated substrates are convenient, the recent development of 
several alternative high-throughput assays utilizing fluorescence or mass spectrometry 
enables the use of unlabeled substrates for nearly all applications.26,28,54,55 Use of unlabeled 
peptides also ensures that acetyllysine preference in multiply-acetylated substrates is not 
skewed by use of the fluorophore. Although we did not observe any significant change in 
acetyllysine preference due to AMC-conjugation in the single peptide tested with KDAC6 
and KDAC8 (Figures 3 and 4), such potential effects should be considered. Utilizing mass 
spectrometry to monitor deacetylation for multiply-acetylated substrates can definitively 
demonstrate whether one or more acetylated lysines are being targeted by the deacetylase. 
Protein acetylation frequently occurs on adjacent or nearby lysine residues (e.g., histones), 
and so this distinction is important both for understanding substrate preference and 
determining kinetic parameters.
While the data presented here did not directly address whether conjugated fluorophores 
modulate the effects of small molecules on KDAC activity, the possibility must be 
considered. Consistent with our data, AMC was previously found to decrease affinity of 
Sirt1 for a peptide substrate.30 Interestingly, this decreased affinity was alleviated by 
resveratrol through a conformational change, and resveratrol had no effect on the activity of 
Sirt1 against the same peptide without AMC.30,31,56 Because the fluorophore specific nature 
of the activation was discovered well after the initial observation, several “activators” of 
Sirt1 were reported, leading to the proposal of an erroneous mechanism to explain how the 
sirtuins extend lifespan in model organisms.17 Subsequent work examining the activation of 
sirtuins has concluded that activating molecules all function allosterically and are substrate-
specific, and therefore AMC-conjugated peptides are not reliable tools for screening of 
potential activators.30-33,57 Additionally, N-acetylthioureas that were reported to activate 
KDAC8 were later found to merely restore basal activity levels for enzymes that were 
functioning well below expected levels,18,41 suggesting that in vitro “activation” of KDACs 
should be treated with skepticism regarding any biological relevance when identified using 
AMC-conjugated substrates. These results may also shed light on the observation that most 
KDAC inhibitors identified in vitro do not have the same effect in cells, as many of the 
screens identifying novel inhibitors utilize AMC-containing peptides. Because AMC 
changes substrate affinity and/or catalytic rate, inhibitors that bind non-competitively (i.e., 
allosterically) may be especially affected by conjugation of these molecules to model 
substrates, as allosteric interactions are most likely to be sensitive to substrate-specific 
events due to the concurrent binding of substrate and modulator. Our observations directly 
demonstrate that KDACs react differently and unpredictably with AMC-containing model 
substrates compared to more biologically relevant substrates. Thus, substrate-specific 
artifacts must be carefully considered and explicitly controlled for when identifying small 
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molecule modulators of KDAC activity. When possible, it would be advantageous to utilize 
KDAC assays that do not rely on fluorophore-conjugated substrates.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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AMC 7-amino-4-methylcoumarin
DMSO dimethyl sulfoxide
GST glutathione S-transferase
KDAC lysine deacetylase
MALDI matrix assisted laser desorption/ionization
MOPS 3-(N-morpholino)propanesulfonic acid
MS mass spectrometry
NAD+ nicotinamide adenine dinucleotide
NMR nuclear magnetic resonance
SAHA suberoylanilide hydroxamic acid
Sirt sirtuin
TEV tobacco etch virus
TOF time-of-flight
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Figure 1. Substrate structures
RG{K-ac} has been reported within several proteins, including as RG{K-ac}W.6,8-11 RH{K-
ac}{K-ac} has been observed within the sequence of cytochrome p53;8 although tryptophan 
does not follow this sequence in any previously reported acetylated protein, we utilize it as 
the closest amino acid mimic of AMC.
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Figure 2. Endpoint activity for KDACs with peptide substrates
Three sets of peptide substrates where the C-terminus ends in an acetylated lysine (blue), 
tryptophan (orange), or AMC (green). Each peptide reacted with KDAC8 (A), KDAC6 (B), 
KDAC4HY (C), or Sirt1 (D) as described in the methods. The average specific activity and 
standard deviation for at least three replicates is shown for each enzyme-substrate pair. The 
differences in trends for each KDAC indicate that AMC conjugation has an effect on enzyme 
activity distinct from tryptophan, the amino acid most similar in structure.
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Figure 3. Deacetylation of doubly acetylated peptide substrates monitored by MALDI MS
Several concentrations of KDAC were reacted with 50 μM doubly acetylated peptides in the 
following pairs: KDAC6 with RH{K-ac}{K-ac}W (A), KDAC6 with RH{K-ac}{K-ac}-
AMC (B), KDAC8 with RH{K-ac}{K-ac}W (C), and KDAC8 with RH{K-ac}{K-ac}-AMC 
(D). After reactions were stopped, they were subjected to MADLI mass spectrometry as 
described in the methods. Peptides were detected based on m/z and identified based on 
theoretical masses of the M+H+ ion for each. Peaks representing the masses of the 
monoisotopic peptides are highlighted for the substrate (green), singly deacetylated product 
(orange), and doubly deacetylated product (blue). The theoretical peptide mass for each is 
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indicated by an arrow. Stars represent the mass of the corresponding potassium adducts, 
observed due to the high salt concentration of the samples from the reaction buffer. For each 
reaction, the most intense signal was set to 1.0, and all other signals were normalized to it. 
The progression of the singly acetylated product matches that expected from fluorescence 
data. The doubly deacetylated product is present for all pairs at the highest concentration of 
KDAC, albeit at very low levels compared to the other peptides.
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Figure 4. Sequence identification for products of doubly acetylated peptide reactions by tandem 
mass spectroscopy
Reactions containing the highest concentration of enzyme from each of the pairs analyzed in 
Figure 3 were subjected to tandem mass spectrometry: KDAC6 with RH{K-ac}{K-ac}W 
(A), KDAC6 with RH{K-ac}{K-ac}-AMC (B), KDAC8 with RH{K-ac}{K-ac}W (C), and 
KDAC8 with RH{K-ac}{K-ac}-AMC (D). Substrate and product peptides (y-axis) were 
subjected to further fragmentation and the resulting y-ion fragments were analyzed. The 
signal/noise ratio for the diagnostic fragments (x-axis) are shown for each parent peptide, 
where white indicates a fragment that was not detected and black indicates high signal/noise 
ratios. All detected fragments were found to have at least 20% of the maximum signal/noise 
ratio, whereas all undetected fragments (white) were entirely absent. Diagnostic fragments 
are those that distinguish between deacetylation at lysine positions 3 and 4; other expected 
y-ion, a-ion, and b-ion peaks were observed but are not as useful for determining the 
acetylation pattern. Note that for the singly deacetylated peptide (1 {K-ac}) from each 
reaction pair, the diagnostic peptide fragment corresponding to deacetylation at position 4 
(KW or K-AMC) was strongly detected, while the fragment corresponding to deacetylation 
at position 3 ({K-ac}W or {K-ac}-AMC) was always absent.
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Tasha B. Toro, Jenae R. Bryant, and Terry J. Watt* 
Department of Chemistry, Xavier University of Louisiana, New Orleans, Louisiana 70125-
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Table S1. NMR peaks for {K-ac} in d6-DMSO. 
Proton(s) δ (ppm) 
Nα (NH) 7.35 (s, 1H) 
Nα acetyl methyl (CH3) 1.84 (s, 3H) 
Cα (CH) 4.13 (m, 1H) 
Cα amide (NH2) 7.86 (d, 2H) 
Cβ (CH2) 1.68 (m, 2H) 
Cγ (CH2) 1.30 (m, 2H) 
Cδ (CH2) 1.55 (m, 2H) 
Cε (CH2) 2.98 (q, 2H) 
Nε (NH) 6.94 (s, 1H) 
Nε acetyl methyl (CH3) 1.78 (s, 3H) 
 
Table S2. Endpoint specific activity (x 10-3 s-1) for KDACs with 100 µM peptide 
substrates 
Substrate KDAC8 KDAC6 KDAC4HY Sirt1 
{K-ac} < 0.1 1.1 ± 0.2 1.1 ± 0.9 1.0 ± 2.0 
{K-ac}W 1.5 ± 0.9 70 ± 30 1.8 ± 0.2 14 ± 10 
{K-ac}-AMC 1.8 ± 0.5 190 ± 30 510 ± 60 0.6 ± 0.1 
RG{K-ac} < 0.1 22 ± 11 2.2 ± 1.4 3.5 ± 1.0 
RG{K-ac}W 1.4 ± 1.1 100 ± 30 3.4 ± 0.7 30.5 ± 1.3 
RG{K-ac}-AMC 3.8 ± 1.7 190 ± 50 460 ± 60 1.0 ± 0.3 
RH{K-ac}{K-ac} 4.3 ± 1.8 25 ± 9 16 ± 4 27.6 ± 1.6 
RH{K-ac}{K-ac}W 9.2 ± 1.4 90 ± 40 26.4 ± 1.6 57.3 ± 0.9 
RH{K-ac){K-ac}-AMC 24 ± 4 230 ± 40 430 ± 90 1.0 ± 0.1 
 
  
S3 
 
Figure S1. SAHA titrations of KDAC6. Endpoint assays of KDAC6 with RG{K-ac} (blue circles) or 
RG{K-ac}-AMC (green squares) in the presence of variable amounts of SAHA, performed as 
described in the methods where reactions were supplemented by 0-800 nmol L-1 SAHA. (A) Specific 
activity. Note the use of two vertical axis scales. (B) Data plotted as percent inhibition, where lines 
represent best-fit to the data. Calculated IC50 values are 4.7 ± 0.9 nmol L-1 and 7.2 ± 0.7 nmol L-1, 
respectively. 
